North East and North Cumbria
ICS Formulary
ICS Formulary
6 Endocrine system
06-04-01-01 Oestrogens and Hormone Replacement Therapy HRT
Links
MHRA Drug Safety Update (Aug 2019): Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping.- NENC ICB - Management of the Menopause
- NENC/Northern Cancer Alliance - Unscheduled Bleed on HRT British Menopause Society guidelines summary for GPs August 2025
- NICE TA160: Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women (Not Approved)
- NICE TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
- NTAG Endocrine System Recommendations